Vol. 4 No. 8 (2024)
Reimbursement Reviews

Infliximab (Remsima SC)

decorative image of the issue cover

Published August 28, 2024

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses Description infliximab (Remsima SC), 120 mg/mL solution for subcutaneous injection.
  • Indication: Maintenance treatment of adults with moderately to severely active Crohn disease who have had an inadequate response to or were intolerant of conventional therapy. Remsima SC should be used only as maintenance therapy after the completion of an induction period with IV infliximab.